Clinical Trials Logo

Clinical Trial Summary

Anemia by the Centers for Disease Control and Prevention (CDC, 1989); It is defined as hemoglobin (Hb) or hematocrit (Hct) values below the 5th percentile in pregnant women. It is expressed as Hb value of 11 mg / dl or Hct value below 33% in the first trimester. II. Less than 10.5 g / dl in trimester can be defined as anemia. Anemia is a risk factor during pregnancy and one of the predisposing causes of maternal death. Pregnancy anemia can be aggravated by various conditions such as uterine or placental bleeding, gastrointestinal bleeding and peripartum blood loss. In addition to the general consequences of anemia, there are specific risks for the mother and fetus during pregnancy such as intrauterine growth retardation, prematurity, feto-placental miss rate, and higher risk for peripartum blood transfusion. Literature studies on anemia in risky age groups during pregnancy (adolescence and advanced age pregnancy) have been reviewed. Some articles and theses published in Turkey and abroad were found. However, the number of studies related to the study subject in Turkey is quite small. For this reason, conducting a research on the effect of anemia on the placenta during pregnancy will lead to a decrease in the gap in the literature and an increase in the awareness of the public on the subject when the research results are obtained. The research is of a prospective type. The universe of the study will be composed of pregnant women who voluntarily agree to participate in the study chosen by the improbable sampling method. According to the anemia of the pregnant women within the scope of the research; I: Group: Anemic pregnancies under the age of 18 (study group), II: Group: Anemic pregnancies over the age of 35 (study group) III: Group : Pregnant women under the age of 18 are not anemic (control group) IV: Group : Non-anemic pregnant women over the age of 35 (control group) as planned. The placentas of pregnant women who gave birth between 37-42 weeks of age and who voluntarily accepted to participate in the study and who were compatible with age and parity will be examined histopathologically, with a total of at least 30 placentas from each group. Those who had an out-of-term delivery, had multiple pregnancy, preeclampsia, gestational diabetes mellitus, thyroid dysfunction, systemic diseases other than anemia, and those who used drugs other than anemia during pregnancy will not be included in the study. The research will only be conducted with women who have a normal vaginal delivery. In our research, it will be examined whether the possible changes that anemia (anemia) will make in the expression of IRP protein 1 produced from the placenta affect the placenta and the baby. In addition, the relationship between IRP protein 1 and primary related TFrP 1 and indirectly changes in DMT1 expressions will be evaluated, so that the intrauterine growth retardation (IUGG), which is one of the negative effects of anemia in pregnancy, and TFrP 1, are the molecules that increase the end-stage release from the placenta. and its relationship in terms of Dmt1 molecules will be investigated. The tissue samples of placenta that will be obtained after the experiment periods, will be buried in paraffin-embedded blocks after routine tissue tracing, and from the obtained blocks, 5 microns of incisions will be taken via microtome, which will then be stained with Hematoxylin-Eosin and then HPL, IGF and leptin expression levels will be examined with the light microscope by immunohistochemical staining. The results of the research data created by determining the effect of the histopathological examinations on the placentas of women with anemia seen in pregnant women in risky age groups will be a source for the next studies. Maternal anemia (of the mother) seen in pregnancies has been studied many times before, but maternal anemia seen in adolescents and advanced age groups will add a different dimension to the subject and will shed light on other studies on the subject. In this way, it is aimed to draw attention to other researches to be carried out to take the necessary measures and measures against these problems.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05644964
Study type Observational [Patient Registry]
Source Celal Bayar University
Contact
Status Completed
Phase
Start date February 17, 2021
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02577536 - PregSource: Crowdsourcing to Understand Pregnancy
Recruiting NCT05899101 - The Impact of Opioid and Cannabis Exposure on Fetal Growth
Completed NCT04168606 - Study on Retroplacental Hematomas in Finistère
Not yet recruiting NCT05284474 - Management of Early-onset Fetal Growth Restriction: Angiogenic Factors Versus Feto-placental Doppler N/A
Completed NCT05771415 - Near-infrared Spectroscopy: Differences in Placental Oxygenation in Relation to Ultrasound Maturation Grade in physiologIcal Term Pregnancies
Completed NCT03764878 - MARS: Magnetic Resonance Study: A Novel Assessment of Placental Function
Recruiting NCT03731949 - Placental Volume Analysis During Pregnanay
Not yet recruiting NCT06352970 - Effects of Tuberculosis Infection on Development and Function of the Placenta
Completed NCT05172674 - Ultrasound Diagnosis of Placental and Umbilical Cord Anomalies in Singleton Pregnancies Resulting From In-vitro Fertilization
Not yet recruiting NCT06314009 - Beyond MARS: Magnetic Resonance Study: A Novel Assessment of Placental Perfusion During Pregnancy
Active, not recruiting NCT04488861 - The START Clinic: a Feasibility Study
Not yet recruiting NCT05872009 - Gestational Diabetes Mellitus: "Placental-maternal Crosstalk and Future Health"
Completed NCT03636698 - Effect of Chorioamnionitis on Platelet Activation and Placental Vessel Among Preterm Infants by Wnt-Flt1 Signal Pathway
Active, not recruiting NCT05739097 - Prospective Study on Feto-maternal outcoMe In aNemIc womEn
Completed NCT05245279 - Placental Perfusion in the Entire Placenta and With Sonobiopsy by Ultrasound N/A
Completed NCT03674606 - Trial of Early Screening Test for Pre-eclampsia and Growth Restriction Phase 4
Recruiting NCT04699578 - COVID-19 Infection and Fetal-neonatal Outcomes
Terminated NCT04525534 - Plasma Concentration of Biological Markers in Placenta Accreta Spectrum